logo

For the Inventor, By the Inventor

Bengaluru, India

Srinivas Cheruku

This inventor holds 16 USPTO granted patents and 1 published patent application and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bristol-Myers Squibb Compnay, Syngene International Limited. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Srinivas Cheruku. Retrieved from https://idiyas.com/inventor/srinivas-cheruku

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16 

% Patents Active = 100.0

 

Average Co-Inventor Count = 8.7

ph-index = 2

Forward Citations = 22(Granted Patents)


Company Filing History:

goldMedal17 out of 3,746 
 
Bristol-Myers Squibb Compnay
 patents
silverMedal1 out of 7 
 
Syngene International Limited
 patents
where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Farnesoid X Receptor Modulators
Indoleamine 2,3-Dioxygenase
Selective NR2B Antagonists
Substituted Amide Compounds
Bicyclic Compounds
Cancer Treatment
IDO Inhibitors
Bridged Bicyclic Compounds
16 patents (USPTO):Explore Patents
1. 12319676 - Substituted amide compounds useful as farnesoid X receptor modulators (2025-06-03),
2. 12227496 - Substituted bicyclic compounds as farnesoid X receptor modulators (2025-02-18),
3. 12145927 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2024-11-19),
4. 12059420 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2024-08-13),
5. 12030835 - Substituted amide compounds useful as farnesoid X receptor modulators (2024-07-09),
6. 11713312 - Substituted bicyclic compounds as farnesoid X receptor modulators (2023-08-01),
7. 11254663 - Substituted bicyclic compounds as farnesoid X receptor modulators (2022-02-22),
8. 11253525 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2022-02-22),
9. 10961229 - Selective NR2B antagonists (2021-03-30),
10. 10954225 - Selective NR2B antagonists (2021-03-23),
11. 10730863 - Bridged bicyclic compounds as farnesoid X receptor modulators (2020-08-04),
12. 10501451 - Selective NR2B antagonists (2019-12-10),
13. 10399932 - Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer (2019-09-03),
14. 10344020 - Selective NR2B antagonists (2019-07-09),
15. 10167254 - IDO inhibitors (2019-01-01),

Title: The Innovative Contributions of Srinivas Cheruku

Introduction

Srinivas Cheruku is a prominent inventor based in Bengaluru, India, known for his significant contributions to the field of pharmaceutical sciences. With a total of 16 patents to his name, he has made remarkable strides in developing compounds that target various medical conditions.

Latest Patents

Among his latest patents, Cheruku has disclosed substituted amide compounds that serve as farnesoid X receptor modulators. These compounds are designed to modulate the activity of the farnesoid X receptor (FXR), which plays a crucial role in various physiological processes. Additionally, he has developed substituted bicyclic compounds that also act as FXR modulators, providing potential therapeutic avenues for conditions such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders.

Career Highlights

Cheruku has worked with notable companies in the pharmaceutical industry, including Bristol-Myers Squibb Company and Syngene International Limited. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research and development in drug discovery.

Collaborations

Throughout his career, Cheruku has collaborated with talented individuals such as Susheel Jethanand Nara and Soodamani Thangavel. These partnerships have fostered innovation and have been instrumental in advancing his research initiatives.

Conclusion

Srinivas Cheruku's work exemplifies the spirit of innovation in the pharmaceutical field. His patents and collaborations highlight his commitment to addressing critical health challenges through scientific advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…